Alexion Pharmaceuticals (ALXN) Shares Declined While Dsm Capital Partners Lifted Its Holding; Sensata Technologies Hldg Bv A Shs (ST) Holder Sumitomo Life Insurance Company Lowered Stake as Share Price Declined

November 15, 2017 - By Marguerite Chambers

Dsm Capital Partners Llc increased its stake in Alexion Pharmaceuticals (ALXN) by 15.11% based on its latest 2017Q2 regulatory filing with the SEC. Dsm Capital Partners Llc bought 153,233 shares as the company’s stock declined 11.63% while stock markets rallied. The hedge fund held 1.17M shares of the health care company at the end of 2017Q2, valued at $142.01 million, up from 1.01 million at the end of the previous reported quarter. Dsm Capital Partners Llc who had been investing in Alexion Pharmaceuticals for a number of months, seems to be bullish on the $24.57B market cap company. The stock decreased 3.06% or $3.47 during the last trading session, reaching $109.98. About 40 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since November 15, 2016 and is downtrending. It has underperformed by 34.82% the S&P500.

Sumitomo Life Insurance Company decreased its stake in Sensata Technologies Hldg Bv A Shs (ST) by 29.91% based on its latest 2017Q2 regulatory filing with the SEC. Sumitomo Life Insurance Company sold 12,024 shares as the company’s stock declined 3.64% while stock markets rallied. The institutional investor held 28,177 shares of the industrial machinery and components company at the end of 2017Q2, valued at $1.20M, down from 40,201 at the end of the previous reported quarter. Sumitomo Life Insurance Company who had been investing in Sensata Technologies Hldg Bv A Shs for a number of months, seems to be less bullish one the $8.10B market cap company. The stock decreased 0.13% or $0.06 during the last trading session, reaching $47.31. About shares traded. Sensata Technologies Holding N.V. (NYSE:ST) has risen 16.67% since November 15, 2016 and is uptrending. It has underperformed by 0.03% the S&P500.




Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Alexion Pharmaceuticals Inc. had 86 analyst reports since July 27, 2015 according to SRatingsIntel. The company was upgraded on Monday, June 27 by Citigroup. Citigroup maintained the stock with “Buy” rating in Tuesday, September 20 report. The stock has “Equal Weight” rating by Barclays Capital on Monday, September 14. On Thursday, November 3 the stock rating was initiated by Deutsche Bank with “Buy”. The stock has “Overweight” rating by Morgan Stanley on Tuesday, June 7. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by RBC Capital Markets on Wednesday, July 13. The rating was initiated by Raymond James on Tuesday, September 1 with “Strong Buy”. Wedbush maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, October 28 with “Neutral” rating. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Friday, June 23. Robert W. Baird maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Tuesday, September 12. Robert W. Baird has “Hold” rating and $145.0 target.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Nasdaq.com which released: “Alexion Pharmaceuticals Inc. Profit Advances 17% In Q3” on October 26, 2017, also Businesswire.com with their article: “Alexion Employees Volunteer Together to Enhance Their Local Communities during …” published on November 09, 2017, Seekingalpha.com published: “Alexion Pharmaceuticals (ALXN) Q3 2017 Results – Earnings Call Transcript” on October 26, 2017. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Nasdaq.com and their article: “Oversold Conditions For Alexion Pharmaceuticals (ALXN)” published on October 26, 2017 as well as Fool.com‘s news article titled: “The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October” with publication date: November 07, 2017.

Since June 14, 2017, it had 4 insider purchases, and 1 insider sale for $235.75 million activity. COUGHLIN CHRISTOPHER J bought 2,000 shares worth $234,200. HANTSON LUDWIG bought $1.17 million worth of stock or 10,000 shares. $97,511 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by PARVEN ALVIN S.

Investors sentiment increased to 1.37 in 2017 Q2. Its up 0.23, from 1.14 in 2017Q1. It is positive, as 55 investors sold ALXN shares while 146 reduced holdings. 72 funds opened positions while 203 raised stakes. 208.01 million shares or 0.31% less from 208.67 million shares in 2017Q1 were reported. Cornerstone Advisors, a Washington-based fund reported 1,809 shares. Bb&T Secs Limited Liability reported 3,154 shares stake. Walleye Trading Ltd Com reported 22,031 shares. Westfield Capital Mngmt Co Ltd Partnership holds 0.34% or 331,270 shares in its portfolio. Cwm Limited Liability Co has 43 shares. Automobile Association holds 114,952 shares or 0.04% of its portfolio. Wms Ltd Llc invested in 0.03% or 2,105 shares. Conning stated it has 0.03% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Delta Asset Management Limited Liability Co Tn reported 15 shares. Td Asset Mgmt Inc has 0.08% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 397,087 shares. Schwab Charles Inv reported 795,572 shares. Sivik Healthcare Ltd Liability Corporation stated it has 4.9% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Hartford Financial Management holds 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 390 shares. Spark Inv Management Ltd Liability accumulated 0.12% or 15,900 shares. Moreover, Lockheed Martin Invest Management Company has 0.11% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 17,200 shares.

Dsm Capital Partners Llc, which manages about $5.78 billion and $6.74B US Long portfolio, decreased its stake in Allergan Plc by 427,265 shares to 324,644 shares, valued at $78.92M in 2017Q2, according to the filing. It also reduced its holding in Monster Beverage by 1.45 million shares in the quarter, leaving it with 4.46 million shares, and cut its stake in Cl C.

Sumitomo Life Insurance Company, which manages about $766.68M US Long portfolio, upped its stake in Xilinx Inc Com (NASDAQ:XLNX) by 30,717 shares to 36,242 shares, valued at $2.33 million in 2017Q2, according to the filing. It also increased its holding in Hcp Inc Com (NYSE:HCP) by 24,785 shares in the quarter, for a total of 40,500 shares, and has risen its stake in Zoetis Inc Cl A (NYSE:ZTS).

Among 13 analysts covering Sensata Technologies Holdings NV (NYSE:ST), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Sensata Technologies Holdings NV had 47 analyst reports since July 30, 2015 according to SRatingsIntel. As per Friday, October 20, the company rating was maintained by Barclays Capital. Cowen & Co maintained Sensata Technologies Holding N.V. (NYSE:ST) on Friday, September 15 with “Hold” rating. The rating was maintained by RBC Capital Markets with “Buy” on Friday, June 9. The stock has “Hold” rating by BMO Capital Markets on Monday, October 16. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, July 25. The company was maintained on Tuesday, July 18 by BMO Capital Markets. The stock of Sensata Technologies Holding N.V. (NYSE:ST) earned “Buy” rating by Stifel Nicolaus on Sunday, September 10. Cowen & Co maintained it with “Hold” rating and $4500 target in Thursday, July 20 report. The company was maintained on Friday, January 15 by RBC Capital Markets. As per Monday, January 9, the company rating was upgraded by RBC Capital Markets.

Analysts await Sensata Technologies Holding N.V. (NYSE:ST) to report earnings on February, 1. They expect $0.84 earnings per share, up 10.53% or $0.08 from last year’s $0.76 per share. ST’s profit will be $143.82M for 14.08 P/E if the $0.84 EPS becomes a reality. After $0.81 actual earnings per share reported by Sensata Technologies Holding N.V. for the previous quarter, Wall Street now forecasts 3.70% EPS growth.

Another recent and important Sensata Technologies Holding N.V. (NYSE:ST) news was published by Seekingalpha.com which published an article titled: “Sensata Technologies Holding’s (ST) CEO Martha Sullivan on Q3 2017 Results …” on October 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: